NASD · Healthcare · Biotechnology · USA
BridgeBio Pharma Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
BridgeBio Pharma is a commercial-stage biopharmaceutical company that discovers and develops medicines for patients with genetic diseases. The company has approved products including Attruby for transthyretin amyloid cardiomyopathy and multiple late-stage programs in development for conditions such as achondroplasia and muscular dystrophy, marketed in the United States and internationally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the BridgeBio Pharma Inc stock.
Overvalued: intrinsic value $2.11 per share, market price $67.55, margin of safety -3103.8% (as of 2026-10-20).
A 2.4x revenue multiple, discounted for its losses, values the shares at $2.11; the price of $67.55 is 3104% above that value.
Leak Score: 33/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
131 more in this industry show a wider margin of safety.
BBIO is overvalued (as of the 2026-10-20 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $2.11; the price of $67.55 is 3104% above that value.
$2.11 per share (as of the 2026-10-20 close), against a market price of $67.55. That is a margin of safety of -3103.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
33 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.